Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk
Open Access
- 24 September 2023
- journal article
- research article
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 43, 100680
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?Journal for ImmunoTherapy of Cancer, 2021
- Prognostic factors after adrenalectomy for adrenal metastasisInternational Urology and Nephrology, 2020
- Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus documentRadiotherapy and Oncology, 2020
- Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialBMC Cancer, 2019
- Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal TumorsAmerican Journal of Roentgenology, 2016
- Vertebral fractures – An underestimated side-effect in patients treated with radio(chemo)therapyRadiotherapy and Oncology, 2016
- Consensus Statement from the International Radiosurgery Oncology Consortium for Kidney for Primary Renal Cell CarcinomaFuture Oncology, 2016